The latest dual PPAR-α/γ agonist in development is aleglitazar (Hoffmann-La Roche), which is currently in the phase III trial to test the hypothesis that aleglitazar (1.5 mg daily dose) can reduce cardiovascular morbidity and mortality in patients with T2DM (NCT01042769). The gene discussed is PPARA; the disease is type 2 diabetes mellitus.